The observed reduction in intracellular ROS, nitrite levels and ROMO1 expression, along with the increased levels of antioxidant defences such as GSH and SOD1, supports the antioxidant potential of TROX in GBM cells. This evidence concerns the gene ROMO1 and glioblastoma.